Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

DNA complexing lipopolythiourea.

Isabelle Tranchant1, Nathalie Mignet, Estelle Crozat

  • 1Laboratoire de Pharmacologie Chimique et Génétique CNRS-UMR 8115, INSERM-U640, ENSCP 11 rue Pierre et Marie Curie 75231 Paris Cedex 05, France.

Bioconjugate Chemistry
|November 18, 2004
PubMed
Summary

A novel neutral lipopolythiourea (DTTU) effectively binds DNA, forming stable liposomes. These DTTU/DPPC liposomes show promise for DNA delivery, enhancing circulation and reducing lung accumulation.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Revisiting the Immunological Landscape of Locoregional Therapies for Gastrointestinal Cancers: A Shift Toward Interventional Immuno-Oncology.

Current oncology reports·2026
Same author

Correction: Bahloul et al. Investigating the Wound-Healing Potential of a Nanoemulsion-Gel Formulation of <i>Pituranthos tortuosus</i> Essential Oil. <i>Gels</i> 2024, <i>10</i>, 155.

Gels (Basel, Switzerland)·2026
Same author

Correction to "Three in One: <i>In Vitro</i> and <i>In Vivo</i> Evaluation of Anticancer Activity of a Theranostic Agent that Combines Magnetic Resonance Imaging, Optical Bioimaging, and Photodynamic Therapy Capabilities".

ACS applied bio materials·2026
Same author

First preclinical evaluation of a thermogel delivering mitomycin C: sustained local release with preserved surgical safety in a large animal model.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·2026
Same author

Pre-clinical evaluation of mRNA-lipid nanoparticles' potency and toxicity: current practices and future directions.

In vitro models·2026
Same author

Machine Learning for the Prediction of Size and Encapsulation Efficiency of mRNA-Loaded Lipid Nanoparticles Following a Postencapsulation Approach.

ACS applied bio materials·2025

Area of Science:

  • Biochemistry
  • Materials Science
  • Nanotechnology

Background:

  • Lipopolythioureas (DTTU) are explored as potential DNA-binding agents.
  • Understanding their interaction with lipids like dipalmitoylphosphatidylcholine (DPPC) is crucial for developing DNA delivery systems.

Purpose of the Study:

  • To investigate the DNA-binding capabilities of a neutral lipopolythiourea (DTTU).
  • To characterize the properties of DTTU/DPPC liposomes and their interaction with DNA.
  • To evaluate the in vivo performance of DTTU-based DNA complexes.

Main Methods:

  • Light scattering experiments to determine particle size and stability.
  • Ethidium bromide accessibility assays to assess DNA binding.
  • Agarose gel electrophoresis to confirm DNA condensation and retention.

Related Experiment Videos

  • In vivo studies involving injection of DTTU/DPPC complexes.

    • Main Results:

    • DTTU/DPPC mixtures formed stable liposomes (100-150 nm) that interacted with DNA.
    • DTTU/DPPC particles, but not DPPC alone, increased in size with DNA addition.
    • DTTU/DPPC limited ethidium bromide accessibility to DNA, indicating association.
    • DTTU/PEG-cholesterol condensed plasmid DNA, unlike cholesterol-PEG(2000) alone.
    • In vivo studies showed increased circulation time and reduced non-specific lung accumulation for DTTU/DPPC complexes.

    Conclusions:

    • Neutral lipopolythiourea (DTTU) demonstrates effective DNA-binding and condensation capabilities.
    • DTTU/DPPC liposomes form stable complexes with DNA, suitable for delivery applications.
    • These non-cationic DTTU-based complexes offer improved pharmacokinetic profiles and reduced organ accumulation compared to cationic alternatives.